The production of therapeutic proteins and peptides is a success story for biology and engineering. Red biotechnology became commercially successful because process engineering succeeded in expressing foreign genes in microorganisms and got a grip on cells: tissue cells were not only cultivated using technical methods but also purified for medical application on an industrial scale. However, the biopharmaceutical industry is now facing rising costs.
Sources:Dirk Weuster-Botz: Bioverfahrenstechnik im Jahrhundert der Biologie. In: Mücke, Wolfgang/Gröger, Gabriele (Eds.): 2. Reisensburger Umweltbiotechnologie-Tag: Anwendungen der Biotechnologie in der chemischen Industrie, p. 25-35John Curling: Process Chromatography: Five Decades of Innovation, in: Biopharm International, February 2007, p. 10ff.Eric S. Langer: Managing Biopharmaceutical Manufacturing Capacity, in: BioProcess International, (3/2007, p. 20-26) 4th annual Report and Survey of Biopharmaceutical Manufacturing and Capacity and Production).Nina Forsberg: 30 Jahre Höhepunkte des Downstream-Processing, in: Bioforum 1/2008, p. 52f.